论文部分内容阅读
应用逆转录－多聚酶链式反应（ＲＴ－ＰＣＲ）技术，检测了３５ 例喉癌患者ＭＤＲ－１ ｍ ＲＮＡ、ＭＲＰｍ ＲＮＡ 基因的表达，同时，应用免疫组化ＳＡＢＣ法检测了６１ 例患者ＭＤＲ－１ 基因产物Ｐ－ｇｐ。喉癌组织中ＭＤＲ－１ ｍ ＲＮＡ 及Ｐ－ｇｐ 的阳性表达率分别为３７．１％ （１３／３５）和３４．４％ （２１／６１）；３５ 例ＲＴ－ＰＣＲ 检测标本中，两项指标间有一定的相关性（Ｐ＜ ０．０１）。晚期患者（Ｔ３－ ４，１８／４０）Ｐ－ｇｐ 阳性表达率明显高于早期患者（Ｔ１－ ２，３／２１，Ｐ＜ ０．０５）。喉癌组织中ＭＲＰｍ ＲＮＡ阳性表达率为４５．７％ （１６／３５），其阳性表达强度在晚期肿瘤中（１４／２３）明显增高（Ｐ＜ ０．０５），且与肿瘤颈淋巴结转移（Ｎ０，８／２７；Ｎ１－ ２，８／８）呈明显相关性（Ｐ＜ ０．０１）
The mRNA expression of MDR-1 m RNA and MRP m RNA in 35 cases of laryngocarcinoma was detected by reverse transcription-polymerase chain reaction (RT-PCR). Meanwhile, immunohistochemical SABC method was used to detect the expression of MDR-1 Gene product P-gp. The positive rates of MDR-1 m RNA and P-gp in laryngeal carcinoma tissues were 37.1% (13/35) and 34.4% (21/61), respectively. Of the 35 RT-PCR specimens, two There is a certain correlation between the indicators (P <0.01). The positive rate of P-gp expression in patients with advanced stage (T3-4, 18/40) was significantly higher than that in early stage (T1- 2, 3/21, P <0.05). The positive expression rate of MRPm RNA in laryngeal carcinoma was 45.7% (16/35). The positive expression rate of MRPmRNA in laryngeal carcinoma was significantly higher than that in advanced stage (14/23) (P <0.05), and it was correlated with cervical lymph node metastasis N0, 8/27; N1-2,8 / 8) were significantly correlated (P <0.01)